Key Takeaways Sanofi gained FDA fast track designation for its gene therapy SAR402663 in wet AMD.The tag allows rolling review, expediting SAR402663's regulatory process.SAR402663 targets VEGF to reduce abnormal eye vessel growth and treatment burden.Sanofi (SNY) announced that the FDA granted fast track designation to its investigational gene therapy, SAR402663, for the treatment of neovascular (or wet) age-related macular degeneration (AMD).How Does the Fast Track Tag Benefit SNY’s Drug Development?Fast t ...